<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04417686</url>
  </required_header>
  <id_info>
    <org_study_id>2019-22</org_study_id>
    <secondary_id>2019-A00746-51</secondary_id>
    <nct_id>NCT04417686</nct_id>
  </id_info>
  <brief_title>ARTERIAL EMBOLIZATION OF PERSISTENT GENICULATE ARTERIES FOR CHRONIC PAIN MANAGEMENT AFTER TOTAL KNEE-REPLACEMENT ARTHROPLASTY(KNEE EMBOLISATION)</brief_title>
  <official_title>ARTERIAL EMBOLIZATION OF PERSISTENT GENICULATE ARTERIES FOR CHRONIC PAIN MANAGEMENT AFTER TOTAL KNEE-REPLACEMENT ARTHROPLASTY: A FEASIBILITY STUDY (KNEE EMBOLISATION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent works in interventional radiology have shown interesting results in the treatment of&#xD;
      musculoskeletal inflammatory sites by arterial embolization. Supra-selective arterial&#xD;
      embolization has been successfully developed by Dr. Okuno (Japan) to manage moderate to&#xD;
      severe knee osteoarthritis. Also, inflammation of the surgical site mediated via geniculate&#xD;
      arteries is a major cause for persistent chronic post-operative gonalgia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Selective arterial embolization of persistent geniculate arteries could reduce&#xD;
      chronic post-operative gonalgia after TKA with minimally invasive approach.&#xD;
&#xD;
      Objective: To evaluate the feasibility of selective arterial embolization of persistent&#xD;
      geniculate arteries to reduce chronic post-operative gonalgia after TKA.&#xD;
&#xD;
      Material and methods: This study is a single-center, prospective, feasibility study. Patients&#xD;
      will be recruited after rheumatology consultation for chronic post-operative gonalgia, more&#xD;
      than 6 months after TKA for moderate to severe gonarthrosis. Eligible patients are adults&#xD;
      with moderate to severe chronic post-operative gonalgia (Visual Analysis Scale (VAS) &gt; 50mm)&#xD;
      and degraded life quality (assessed by SF36 score), despite at least 3 months of optimal&#xD;
      medical treatment. Non-inclusion criteria are mainly other rheumatologic or orthopedic severe&#xD;
      diseases, severe surgical complications. Under local anesthesia, with homolateral antegrade&#xD;
      femoral access, patient will undergo selective arterial embolization of persistent and&#xD;
      aberrant peri-prosthetic arteries using HydroPearl® 200µm Mircospheres. Follow-up&#xD;
      consultations will be scheduled at D1, M1, M3, M6 and M12. For a significance level of α=0.05&#xD;
      and power of 80% we require a cohort of 24 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>arterial embolization</measure>
    <time_frame>12 MONTHS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS pain score</measure>
    <time_frame>12MONTHS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and Universities Osteroarthritis Index (WOMAC) score</measure>
    <time_frame>12MONTHS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 quality of life score</measure>
    <time_frame>12 MONTHS</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Musculoskeletal Inflammatory</condition>
  <arm_group>
    <arm_group_label>patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>arterial embolization</intervention_name>
    <description>arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis</description>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient (male or female) aged 18-85&#xD;
&#xD;
          -  Suffering from moderate to severe chronic pain (EVA &gt; 50mm) more than 6 months after&#xD;
             total prosthetic knee replacement surgery for severe gonarthrosis with impact on&#xD;
             quality of life.&#xD;
&#xD;
          -  And having followed for at least 3 months a well-conducted conservative medical&#xD;
             treatment (anti-inflammatory, analgesic, masso-kinesiotherapy).&#xD;
&#xD;
          -  The patient may initially have had a single or bilateral replacement. The period of 6&#xD;
             months must be respected for each side, between the intervention and the inclusion for&#xD;
             homolateral pain.&#xD;
&#xD;
          -  Patient willing to participate in the study and with signed informed consent.&#xD;
&#xD;
          -  Patient willing to undergo post-operative monitoring for one year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Orthopaedic or rheumatological pathologies:&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Psoriatic rheumatism&#xD;
&#xD;
          -  Spondylarthropathies&#xD;
&#xD;
          -  History of primary or secondary bone tumor, in remission or active.&#xD;
&#xD;
          -  Myeloma&#xD;
&#xD;
          -  Operational criteria:&#xD;
&#xD;
          -  Infection of the surgical site&#xD;
&#xD;
          -  Re-operation&#xD;
&#xD;
          -  Severe bleeding&#xD;
&#xD;
          -  Use of turnstile per-operative&#xD;
&#xD;
          -  Wound of popliteal artery&#xD;
&#xD;
          -  Diabetic patient&#xD;
&#xD;
          -  Comorbidities:&#xD;
&#xD;
          -  General condition responsible for objective hemostasis disorder (hemophilia,&#xD;
             Willebrand disease, thrombocytopenia) and anticoagulant treatments.&#xD;
&#xD;
          -  Pads 100 G/L&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EMILIE GARRIDO PRADALIE</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>vincent VIDAL</last_name>
    <email>vincent.vidal@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>drci@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>vinent vidal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

